Capricor Therapeutics (NASDAQ:CAPR) Sees Unusually-High Trading Volume – Time to Buy?

Capricor Therapeutics Inc (NASDAQ:CAPR) shares saw strong trading volume on Friday . 413,080 shares traded hands during mid-day trading, a decline of 47% from the previous session’s volume of 773,235 shares.The stock last traded at $15.54 and had previously closed at $14.96.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They set an “overweight” rating and a $35.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a research note on Thursday. Maxim Group raised their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th. Cantor Fitzgerald boosted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a research report on Monday, September 23rd. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $34.50.

Capricor Therapeutics Stock Up 5.3 %

The business’s 50-day moving average is $16.82 and its two-hundred day moving average is $10.81. The company has a market capitalization of $716.61 million, a P/E ratio of -14.87 and a beta of 3.98.

Hedge Funds Weigh In On Capricor Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Main Street Financial Solutions LLC boosted its position in Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $133,000. Rhumbline Advisers bought a new position in Capricor Therapeutics during the second quarter valued at about $147,000. The Manufacturers Life Insurance Company purchased a new stake in Capricor Therapeutics during the third quarter worth about $161,000. Finally, Sassicaia Capital Advisers LLC bought a new stake in Capricor Therapeutics in the third quarter worth about $192,000. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.